BioStem Technologies, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
BioStem Technologies, Inc. (BSEM) reported Revenue from Contract with Customer, Excluding Assessed Tax of $7.90 million for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-18.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-09-18
- BioStem Technologies, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $7.90M, a 27.95% decline year-over-year.
- BioStem Technologies, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $10.96M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $7.90M S-1 · filed 2026-09-18 | $14.03M S-1 · filed 2026-09-18 |
| 2025-06-30 | $10.96M S-1 · filed 2026-09-18 | $26.93M S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |